The Role of Bisphosphonates for the Treatment of Bone Disease in Multiple Myeloma

References

• Mundy G.R, Bertolini D.R. Bone destruction and hypercalcemia in multiple myeloma. Semin. Hematol. 1986; 13: 291–299
   Google Scholar
• Ascari E., Merlini G., Riccardi A. La malattia ossea mielomatosa. Proceedings of the XXXIV Congress of the Italian Society of Internal Medicine. 1989; 326–333
   Google Scholar
• Weinstein R.S. Bone involvement in multiple myeloma. Am. J. Med. 1992; 93: 591–594
   PubMed Web of Science ®Google Scholar
• Kyle R.A. Multiple myeloma: review of 969 cases. Mayo Clin. Proc 1975; 50: 29–40
   PubMed Web of Science ®Google Scholar
• Wisloff F., Eika S., Hippe E., Hjoerth M., Holmberg E., Kaasa S., Palva I., Westin J., for the Nordic Myeloma Study Group. Measurement of health-related quality of life in multiple myeloma. Br. J. Haematol. 1996; 92: 604–613
   PubMed Web of Science ®Google Scholar
• Rosol T.J, Capen C.C. Mechanisms of cancer-induced hypercalcemia. Lab. Invest. 1994; 67: 680–702
   Web of Science ®Google Scholar
• Bataille R., Manolagas S.C, Berenson J.R. Pathogenesis and management of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North Am.: Multiple myeloma 1997; 11: 285–295
   Google Scholar
• Bataille R., Delmas P.D, Chappard D., Sany J. Abnormal serum bone gla-protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer 1990; 66: 167–172
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Alexander C., Sany J. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br. J. Cancer 1986; 53: 805–810
   PubMed Web of Science ®Google Scholar
• Bataille R., Chappard D., Marcelli C., Dessauw P., Sany J., Baldet P., Alexandre C. The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest. 1991; 88: 62–66
   PubMed Web of Science ®Google Scholar
• Vinholes J., Guo C.Y, Purhoit O.P, Eastell R., Coleman R.E. Evaluation of new bone resorption in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancies. J. Clin. Oncol. 1997; 15: 131–138
   PubMed Web of Science ®Google Scholar
• Mundy G.R, Raisz R.G, Cooper R.A, Schechter G.P, Salmon S.E. Evidence for the secretion of an osteoclast stimulating factor in multiple myeloma. N. Engl. J. Med. 1974; 291: 1041–1046
   PubMed Web of Science ®Google Scholar
• Klein B., Bataille R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am.: Multiple myeloma 1992; 6: 273–284
   PubMed Web of Science ®Google Scholar
• Manolagas S.C, Jilka R. Bone marrow, cytokines and bone remodelling. N. Engl. J. Med. 1995; 332: 305–311
   PubMed Web of Science ®Google Scholar
• Bertolini D.R, Nedwin G.E, Bringman T.S, Smith D.D., Mundy G. Stimulation of bone resorption and inhibition of bone formation in vitro by tumor necrosis factor. Nature 1986; 319: 516–518
   PubMed Web of Science ®Google Scholar
• Kawano M., Yamamoto Y., Iwato K. Interleu-kin-1 beta rather than lymphotoxin as a major bone resorbing activity in multiple myeloma. Blood 1989; 73: 1646–1649
   PubMed Web of Science ®Google Scholar
• Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 1990; 144: 4226–4230
   Web of Science ®Google Scholar
• Mundy G.R. Cytokines and local factors which affect osteoclast function. Int. J. Cell Clon. 1992; 10: 215–222
   PubMedGoogle Scholar
• Stashenko P., Dewhirst F.E, Peros W.J. Synergistic interactions between interleukin-1, tumor necrosis factor and lymphotoxin in bone resorption. J. Immunol. 1987; 138: 1464–1470
   PubMed Web of Science ®Google Scholar
• San Miguel J.F. (1996) Supportive therapy for complications in multiple myeloma Education Programme of the 2nd European Hematology Association Congress. 29 May-1 June, 1996. Paris, 12–16
   Google Scholar
• Montillo M., Tedeschi A., Capelli D., Leoni P. Lesioni ossee ed ipercalcemia. II. mieloma multiplo: attualita' di biologia e terapia, E. Morra. Eliotecnica Grafica, Cornaredo 1996; 89–102
   Google Scholar
• Rodriguez L.H, Finkelstein J.B, Schullenberger C.C, Alexanian R. Bone healing in multiple myeloma with melphalan chemotherapy. Ann. Int. Med. 1972; 76: 551–556
   Web of Science ®Google Scholar
• Kyle R.A, Jowsey J., Kelly P.J, Taves D.R. Multiple myeloma bone disease: the comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med. 1975; 293: 1334–1338
   PubMed Web of Science ®Google Scholar
• Cohen H.J, Silberman H.R, Trnyos K., Bartolucci A.A, the Southeastern Cancer Study Group. Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984; 63: 639–648
   PubMed Web of Science ®Google Scholar
• Warrel R.P, Murphy W.K, Schulman P., O'Dwyer P., Heller G. Gallium nitrate for the treatment of cancer related hypercalcemia: a randomized double-blind comparison to etidronate. J. Clin. Oncol. 1991; 9: 1467–1475
   PubMed Web of Science ®Google Scholar
• Harley J.B, Schilling A., Glidewell O., for the Acute Leukemia Study Group B. and Eastern Cooperative Oncology Group. Ineffectiveness of fluoride therapy in multiple myeloma. N. Engl. J. Med. 1972; 286: 1283–1288
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: pharmacology and use in treatment of tumor induced hypercalcaemia and metastatic bone disease. Drugs 1991; 42: 919–944
   PubMed Web of Science ®Google Scholar
• Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18: 75–85
   PubMed Web of Science ®Google Scholar
• Rodan G.A, Fleisch H.A. Bisphosphonates: mechanisms of action. J. Clin. Invest. 1996; 97: 2692–2696
   PubMed Web of Science ®Google Scholar
• Jantunen E., Laakso M. Bisphosphonates in multiple myeloma: current status, future perspectives. Br. J. Haematol. 1996; 93: 501–506
   PubMed Web of Science ®Google Scholar
• Savage A.D, Belson D.J, Vescio R.A., Lichtenstein A.K, Berenson J.R. Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood 1996; 88: 105a, abstract
   Web of Science ®Google Scholar
• Purohit O.P., Radstone C.R, Owen J., Anthony C., Coleman R.E. High dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer 1994; 70: 554–558
   PubMed Web of Science ®Google Scholar
• Bataille R. Management of myeloma with bisphosphonates. N. Engl. J. Med. 1996; 334: 529–530
   PubMed Web of Science ®Google Scholar
• Paterson A.D, Kanis J.A, Cameron E.C. The use of dichloromefhylene diphosphonate for the management of hypercalcemia in multiple myeloma. Br. J. Haematol. 1983; 54: 121–132
   PubMed Web of Science ®Google Scholar
• Nussbaum S.R, Younger J., Vandepol C.J. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30, 60 and 90 mg dosages. Am. J. Med. 1993; 95: 297–304
   PubMed Web of Science ®Google Scholar
• Purhoit O.P, Radstone C.R, Anthony C., Kanis J.A, Coleman R.E. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br. J. Cancer 1995; 72: 1289–93
   PubMed Web of Science ®Google Scholar
• Gucalp R., Ritch P., Weimik P.H., Sarma PR., Keller A., Richman S.P, Tauer K., Neidhart J., Mallette L.E, Siegel R., Vanderpol C.J. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J. Clin. Oncol. 1992; 10: 134–142
   PubMed Web of Science ®Google Scholar
• O'Rourke N.P, McCloskey E.V, Vasikaran S., Eyres K., Fern D., Kanis J.A. Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br. J. Cancer 1993; 67: 560–563
   PubMed Web of Science ®Google Scholar
• Ralston S.H, Gallagher S.J, Patel U., Dryburgh F.J, Fraser W.D, Cowan R.A, Boyle I.T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 1989; 2: 1180–1182
   PubMed Web of Science ®Google Scholar
• Singer F.R. Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. Semin. Oncol. 1990; 17: 24–38
   Google Scholar
• Thiebaud D., Jaeger P., Jacquet A.F, Burckhardt P. Dose response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP (APD). J. Clin. Oncol. 1988; 6: 762–768
   PubMed Web of Science ®Google Scholar
• Jacobs T.P, Siris E.S, Bilezikian J.P, Baguiran D.C, Shane E., Canfield R.E. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann. Int. Med. 1981; 94: 312–316
   PubMed Web of Science ®Google Scholar
• Percival R.C, Paterson A.D, Yates A.J.P. Treatment of malignant hypercalcemia with clodronate. Br. J. Cancer 1985; 51: 665–669
   PubMed Web of Science ®Google Scholar
• Siris E.S, Sherman W.H, Baquiran D.C, Schlatterer J.P, Osserman E.F, Canfield R.E. Effects of dichloromethylene diphosphonate on skeleton mobilization of calcium in multiple myeloma. N. Engl. J. Med. 1980; 302: 310–315
   PubMed Web of Science ®Google Scholar
• Urwin J.H, Yates A. J.P, Gray R.E.S., Hamdy N.A.T., McCloskey E.V., Preston F.E, Greaves M., Neil F.E, Kanis J.A. Treatment of hypercalcemia of malignancy with intravenous clodronate. Bone 1987; 8(suppl. 1)S43–S51
   PubMedGoogle Scholar
• Body J.J, Dumon J.C. Treatment of tumor induced hypercalcemia with the bisphosphonate pamidronate. Ann. Oncol. 1994; 359–363
   PubMed Web of Science ®Google Scholar
• Jung A. Comparison of two parental diphosphonates in hypercalcemia of malignancies. Am. J. Med. 1982; 72: 221–226
   PubMed Web of Science ®Google Scholar
• Belch A.R, Bergsagel D.E, Wilson K., O'Reilly S., Wilson J., Sutton D., Pater J., Johnston D., Zee B. Effect of daily etidronate on the osteolysis in multiple myeloma. J. Clin. Oncol. 1991; 9: 1397–1402
   PubMed Web of Science ®Google Scholar
• Daragon A., Humez C., Michot C., Le Loet X., Grosbols B., Pouyol F., Euller-Ziegler L., Azais I., Bernard J.F, Menard J.F, Monconduit M., for the Groupe d'Etudes et de Recherches sur le Myelome (GERM). Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur. J. Med. 1993; 2: 449–452
   PubMedGoogle Scholar
• Delmas P.D, Charhon S., Chapuy M.C, Vignon E., Brian-Con D., Edouard C., Meunier P.J. Long term effects of dichloromethylene dis-phosphonate (C12-MDP) on skeletal lesions in multiple myeloma. Metab. Bone. Dis. Relat. Res. 1982; 4: 163–168
   PubMedGoogle Scholar
• Merlini G., Parrinello G.A, Piccinini L., Crema R., Fioren-Tini M.L., Riccardi A., Pavesi R., Novazzi R., Silingardi V., Ascari E. Long term effects of parenteral dichloromethylene biphosphonate (C12-MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol. Oncol. 1990; 8: 23–30
   PubMed Web of Science ®Google Scholar
• Lahtinen R., Laakso M., Palva I., Virkkumen P., Elo-Maa P., for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049–1052
   PubMed Web of Science ®Google Scholar
• Laakso M., Lahtinen R., Virkkumen P., Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br. J. Haematol. 1994; 87: 725–729
   PubMed Web of Science ®Google Scholar
• Laakso M., for the Finnish Leukaemia Group. Clodronate for multiple myeloma. Lancet 1993; 341: 175–176
   Web of Science ®Google Scholar
• Clemens M.R, Fessele K., Heim M.E. Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann. Hematol. 1993; 66: 141–146
   PubMed Web of Science ®Google Scholar
• Heim M.E, Clemens M.R, Queisser W., Pecherstorfer M., Boewer C., Herold M., Franke A., Hermann Z., Looser R., Edler L. Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkolo-gie 1995; 18: 439–448
   Web of Science ®Google Scholar
• McCloskey E.V, MacLennan I.C.M., Drayson M., Chapman C., Dunn J., Kanis J.A. Effects of clodronate on morbidity and mortality in myelomatosis. Ann. Oncol. 1996; 7(suppl. 5)4120, abstract
   Google Scholar
• Man Z., Otero A.B, Rendo P., Barazzutti L., Sanchez Avalos J.C. Use of pamidronate for multiple myeloma osteolytic lesions. Lancet 1990; 335: 663
   PubMed Web of Science ®Google Scholar
• Thiebaud D., Leyvraz S., von Fliedner V., Perey L., Comu P., Thiebaud S., Burckardt P. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur. J. Cancer 1991; 27: 37–41
   PubMed Web of Science ®Google Scholar
• Thurlimann B., Morant R., Jungi W.R, Radziwill A. Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support. Care Cancer 1994; 2: 61–65
   PubMed Web of Science ®Google Scholar
• Berenson J.R, Lichtenstein A., Porter L., Dimopoulos M.A, Bordoni R., George S., Lipton A., Keller A., Ball-Ester O., Kovacs M.J, Blacklock H.A, Bell R., Simeone J., Reitsma D.J, Heffernan M., Seaman J., Knight D., for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 1996; 334: 488–493
   PubMed Web of Science ®Google Scholar
• Berenson J.R, Lichtenstein A., Porter L., Dimopoulos M.A, Bordoni R., George S., Lipton A., Keller A., Ball-Ester O., Kovacs M., Blacklock H., Bell R., Simeone G.F, Reitsma D.J, Heffernan M., Seaman J., Knight D. Long term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J. Clin. Oncol. 1998; 16: 593–602
   PubMed Web of Science ®Google Scholar
• Berenson J.R. (1997) Bisphosphonate therapy of myeloma. VI International Worshop on Multiple Myeloma. June 14-18, 1997. Syllabus, Boston
   Google Scholar
• Anderson K., Kyle R.A, Berenson J. (1997) Multiple myeloma. Education Program. 39th Annual Meeting American Society of Hematology. December 5-9, 1997. SDiego, 177–188
   Google Scholar
• Musto P., Falcone A., Bodenizza C., Vigliotti M.L, Sanpaolo G., De Renzo A., Rotoli B., Carotenuto M. Pamidronate has significant effects on bone disease of patients with advanced multiple myeloma. Multiple Myeloma: Advances in Biology and Treatment. Wien. September 13-14, 1996; 70, 1996(abstract)
   Google Scholar
• Attal M., Harousseau J.L, Stoppa A.M, Sotto J.J, Fuzi-Bet J.G., Rossi J.R, Casassus P., Maissoneuve H., Facon T., Ifrah N., Payen C., Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Barlogie B., Jagannath S., Vesole D., Tricot G., Naucke S., Cheson B., Mattox S., Bracy D., Jacobson J., Crowley J. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Palumbo A., Argentino C., Dominietto A., Frieri R., Avvisati G., Comotti B., Lauta V.M, Liberati M., Marmont R., Musto P., Tribalto M., Pileri A. Conventional induction treatments do not influence overall survival in multiple myeloma. Br. J. Haematol. 1997; 96: 333–337
   PubMed Web of Science ®Google Scholar
• Morton A. The role of bisphosphonates in patients with bony metastases. Cancer J. 1995; 8: 231–233
   Web of Science ®Google Scholar
• Fitton A., McTavish D. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1991; 41: 289–318
   PubMed Web of Science ®Google Scholar
• Plosker G.L, Goa K.L. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945–982
   PubMed Web of Science ®Google Scholar
• De Groen P.C, Lubbe D.F, Hirsch L.J, Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J, Pinkas H., Wang K.K. Esoph-agitis associated with the use of alendronate. N. Engl. J. Med. 1996; 335: 1016–1021
   PubMed Web of Science ®Google Scholar
• Tyrrell C.J, Collisons M., Madsen E.I, Ford J.M, Coleman T. Intravenous pamidronate: infusion rate and safety. Ann. Oncol. 1994; 5: 37–40
   PubMedGoogle Scholar
• Savage A.D, Belson D.J, Vescio R.A. Pamidronate reduces IL-6 production by bone marrow dendritic cell coltures in a dose and drug potency dependent manner. 1998, Submitted for publication
   Google Scholar
• Shipman CM., Rogers M.J, Apperley J.R, Russel G.G, Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol. 1997; 98: 665–672
   PubMed Web of Science ®Google Scholar
• Aparicio A., Gardner A., Tu Y. In vitro cytore-ductive effects of multiple myeloma cells induced by bisphosphonates. Leukemia 1998, (in press)
   PubMed Web of Science ®Google Scholar
• Gerz B.J, Holland S.D, Kline W.R, Matuszewsky B.K, Porras A.G. Clinical pharmacology of alendronate sodium. Osteop. Intern. 1993; 3(suppl. 3)S13–S16
   PubMedGoogle Scholar
• Reginster J.Y.L. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992; 13: 351–354
   PubMed Web of Science ®Google Scholar
• Roux C., Ravaud P., Cohen-Solal M., De Veraejoul M.C, Guillemant S., Cherrau B., Delmas P., Dougados M., Amor B. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15: 41–49
   PubMed Web of Science ®Google Scholar
• Green J.R, Muller K., Jaeggi K.A. Preclinical pharmacology of CGP 42446, a new potent, heterocyclic bisphosphonate compound. J. Bone Miner. 1994; 9: 745–750
   PubMed Web of Science ®Google Scholar